Mosaic Immunoengineering Inc (CPMV) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Mosaic’s ability to generate operating leverage and fund strategic growth despite commodity volatility, while the biosciences segment offers a high‑margin diversification path for shareholders.

Key Takeaways

• North America sales outperformed industry declines
• Q4 phosphate output 1.7M tons despite turnaround
• $150M cost savings achieved; $100M target for 2026
• Sulfur price spike compresses phosphate margins into 2026
• Mosaic Biosciences doubled 2025 sales, targeting another double

Pulse Analysis

The Mosaic Company demonstrated notable resilience in 2025, with its North American segment gaining market share despite a sector‑wide decline in potash and phosphate shipments. Phosphate output reached 1.7 million tons in Q4, and the firm projects at least 7 million tons for 2026, while potash production is expected to hold near 9 million tons. Aggressive cost‑reduction initiatives delivered $150 million of savings ahead of schedule, and a further $100 million is targeted for the coming year. However, an end‑of‑year sulfur price spike is expected to compress margins in the phosphate and Fertilizantes segments well into 2026, adding pressure to cash flows.

Growth momentum is shifting toward Mosaic Biosciences, which doubled net sales to $68 million in 2025 and posted gross margins above 40 percent. The business launched five new products and secured registrations in more than 60 markets across 16 countries, positioning it as a scalable, high‑margin platform. Management aims to replicate the 2025 growth trajectory in 2026, with a second doubling of sales driven by eight to ten additional product launches. This diversification reduces reliance on commodity fertilizer cycles and offers investors a pathway to incremental earnings resilience as traditional margins face commodity‑price volatility.

Capital allocation reflects a disciplined shift toward core assets and strategic growth. The company completed divestitures of Patos de Minas, Taquari and is pursuing the Carlsbad sale, generating roughly $170 million in proceeds and cutting $60 million in asset‑retirement obligations. CapEx is slated at $1.5 billion in 2026, primarily for mine, gyp‑stack and tailings projects, but is expected to fall to $1 billion by 2030. Management anticipates a $300‑$500 million working‑capital release as inventory levels normalize, which should lift EBITDA‑to‑cash conversion back toward historic 70 percent levels and support debt reduction and potential extraordinary shareholder returns.